🔗 Share this article

A shadow economy for unapproved slimming drugs is being driven by social media fitness personalities and sellers on communication apps, based on new investigations.

Experimental Treatment Gaining Traction Via Social Media

Retatrutide, which is still in research studies, is being advertised by online personalities for its supposed fat-burning effects. Viewers are urged to contact these accounts privately for source information, while also receiving discount codes.

Thriving Trade on Social Networks

Separately, a robust trade exists on messaging services, where communities with numerous of members share comparison photos, administration instructions and assertions of next-day British shipping. Sellers market the drug there before redirecting buyers to WhatsApp for transactions.

Understanding The Experimental Drug

This medication is an investigational injection created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – GLP-1, GIP and glucagon. Early trials suggest it could assist individuals lose up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being hailed digitally as the next Ozempic.

Medical Professionals Voice Worries

However, doctors and pharmacists have cautions that the sale of what remains an unlicensed medication in the UK is worrisome and could result in users administering products of unknown origin.

Some professionals stated the demand for the experimental drug could be connected to the increasing cost of approved slimming treatments such as Mounjaro.

Regulatory Position and Enforcement

Marketing the unapproved drug on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.

Several influencers attempt to circumvent the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and supply can still violate pharmaceutical, advertising, and consumer laws, potentially leading to fines, legal action or imprisonment.

Service Reaction and Content Removal

According to the social media company, the service has taken down problematic content and prohibited related hashtags and query recommendations. The company stated it was dedicated to keeping the platform safe and investing in strengthening enforcement strategies.

Online Trading Operations

Investigations also found groups with up to nine thousand members selling the experimental drug using the platform's built-in search feature, which functions like a public directory. Entering “retatrutide” instantly displays channels with thousands of members, populated with images of weight loss, glowing reviews and detailed guides for mixing or administering at home.

Within minutes of joining one community, a vendor posted WhatsApp details, where most transactions take place. The seller provided an guidebook and promised shipping within two days. When asked whether the product was genuine, one seller responded: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. None inquired about weight, medical conditions or previous experience.

Product Information and Pricing

Within these communities, posts show dark colored parcels with Royal Mail labels, claiming to contain new batches. One communication read: “It took eight of us to load them this morning.”

Buyers can select between powder vials, prepared at home with sterile water, or ready-to-use pens usually sold at £160 for 20mg. When questioned how much time a pen should be used, vendors give conflicting answers ranging from a few weeks to “depends on your body”.

Platform Oversight and Security Actions

A representative for Telegram stated it regularly moderated harmful material on its platform including material that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“Individuals are administering substances they cannot confirm. Even if the research behind retatrutide is valid, these online products may not contain what they claim,” stated Jason Murphy, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service connected the surge in demand to current cost increases for approved slimming medications such as Mounjaro. “With prices increasing, individuals are turning to online platforms. But fake treatments are highly risky. You cannot know what’s inside or whether the conditions they were produced in was sterile,” she explained.

Her team has already encountered individuals injured by personal administration from unconfirmed sources. “We understand the frustration, but purchasing from Telegram or communication platforms is taking chances with your well-being,” said the doctor. “These materials could be impure or improperly measured.”

Manufacturer Statement

A spokesperson from Eli Lilly stated the substance was in third stage clinical trials and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they said, noting that any product “misleadingly claiming itself as a company investigational product not yet authorized … may expose patients to potentially serious health risks”.